These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 14345319)

  • 1. [PSYCHIC ESTROGEN EFFECTS IN MALES. PROSTATIC PATIENTS TREATED WITH POLYESTRADIOL PHOSPHATE (ESTRADURIN)].
    PETERSEN P
    Arch Psychiatr Nervenkr; 1964 Dec; 206():382-405. PubMed ID: 14345319
    [No Abstract]   [Full Text] [Related]  

  • 2. [ESTROGEN-INDUCED CHANGES IN PROSTATE PATIENTS. PHYSICAL AND MENTAL EFFECTS IN 29 PATIENTS TREATED WITH ESTRADURIN-POLYESTRADIOL PHOSPHATE].
    PETERSEN P; ZINGG E
    Urol Int; 1965; 19():317-25. PubMed ID: 14316549
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin) in prostatic cancer patients.
    Stege R; Gunnarsson PO; Johansson CJ; Olsson P; Pousette A; Carlström K
    Prostate; 1996 May; 28(5):307-10. PubMed ID: 8610057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical observation of polyestradiol phosphate (estradurin) in treatment of prostatic carcinoma.
    MOOKINI RK; KELLY EF
    J Urol; 1960 Jan; 83():72-3. PubMed ID: 14423802
    [No Abstract]   [Full Text] [Related]  

  • 5. [Polyestradiol phosphate (estradurin) in prostate carcinoma].
    ZUERCHER P
    Helv Chir Acta; 1960 Oct; 27():500-5. PubMed ID: 13788928
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of advanced prostatic carcinoma using polyestradiol phosphate (Estradurin)].
    Bülow H
    Med Welt; 1980 Aug; 31(34):1215-7. PubMed ID: 6776381
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer of the prostate; further observations with estradurin (polyestradiol phosphate).
    GOODHOPE CD
    Postgrad Semin Am Urol Assoc North Cent; 1957; ():170-1. PubMed ID: 13554425
    [No Abstract]   [Full Text] [Related]  

  • 8. Polyestradiol phosphate and ethinyl estradiol in treatment of prostatic carcinoma.
    Lindstedt E
    Scand J Urol Nephrol Suppl; 1980; 55():95-7. PubMed ID: 6938044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testicular steroid secretion and peripheral serum steroid concentrations in patients with prostatic carcinoma after short-term estrogen treatment.
    Lukkarinen O; Hammond GL; Kontturi M; Vihko R
    Invest Urol; 1979 May; 16(6):453-6. PubMed ID: 447478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of endocrine therapy on plasma steroids in prostatic carcinoma patients.
    Drafta D; Proca E; Schindler AE; Neacşu E; Zamfir V; Neagoe M; Teodosiu D
    Endocrinologie; 1984; 22(3):191-7. PubMed ID: 6494786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of estramustine phosphate (Estracyt) in patients with prostatic carcinoma.
    Andersson SB; Gunnarsson PO; Nilsson T; Forshell GP
    Eur J Drug Metab Pharmacokinet; 1981; 6(2):149-54. PubMed ID: 7274309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate.
    Henriksson P; Eriksson A; Stege R; Collste L; Pousette A; von Schoultz B; Carlström K
    Prostate; 1988; 13(3):257-61. PubMed ID: 3211807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of prostatic carcinoma with various types of estrogen derivatives.
    Jönsson G; Olsson AM; Luttrop W; Cekan Z; Purvis K; Diczfalusy E
    Vitam Horm; 1975; 33():351-76. PubMed ID: 1229063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of platelet aggregation caused by estrogen treatment in patients with carcinoma of the prostate.
    Eisen M; Napp HE; Vock R
    J Urol; 1975 Jul; 114(1):93-7. PubMed ID: 1142508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma concentrations of estradiol and testosterone in single-drug polyestradiol phosphate therapy for prostatic cancer.
    Norlén BJ; Fritjofsson A; Grönquist L; Gunnarsson PO; Johansson SA; Plym-Forshell G
    Eur Urol; 1987; 13(3):193-7. PubMed ID: 3609099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum sex hormone binding globulin and testosterone binding after estradiol administration, castration, and their combination in men with prostatic carcinoma.
    Leinonen P; Hammond GL; Lukkarinen O; Vihko R
    Invest Urol; 1979 Jul; 17(1):24-7. PubMed ID: 571863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of orchiectomy and polyestradiol phosphate therapy on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients.
    Aro J; Haapiainen R; Sane T; Rannikko S; Pelkonen R; Alfthan O
    Eur Urol; 1990; 17(3):229-35. PubMed ID: 2351192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
    Hedlund PO; Damber JE; Hagerman I; Haukaas S; Henriksson P; Iversen P; Johansson R; Klarskov P; Lundbeck F; Rasmussen F; Varenhorst E; Viitanen J;
    Scand J Urol Nephrol; 2008; 42(3):220-9. PubMed ID: 18432528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adrenocortical function in prostatic cancer patients: effects of orchidectomy or different modes of estrogen treatment on basal steroid levels and on the response to exogenous adrenocorticotropic hormone.
    Carlström K; Stege R
    Urol Int; 1990; 45(3):160-3. PubMed ID: 2161578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. A preliminary report from a randomized multicenter study.
    Lundgren R; Sundin T; Colleen S; Lindstedt E; Wadström L; Carlsson S; Hellsten S; Pompeius R; Holmquist B; Nilsson T
    Scand J Urol Nephrol; 1986; 20(2):101-5. PubMed ID: 3529368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.